Description
APP (Aducanumab Biosimilar) Human mAb was confirmed to bind to its intended target aggregated Aβ using bio-layer interferometry. APP (Aducanumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Aducanumab is an antibody directed against aggregated Aβ.
Target
APP
Target Alias Name
APP
Isotype/Mimetic
IgG kappa
Animal-Derived Biomaterials Used
BSA
Sequence Available
Yes
Original Discovery Method
Immunization
Antibody/Binder Origins
Animal-dependent discovery, post-2020, In vitro recombinant expression, Animal-derived biomaterials used in production or final formulation